Compare WNEB & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WNEB | LCTX |
|---|---|---|
| Founded | 1853 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 264.8M | 255.4M |
| IPO Year | 2001 | 1996 |
| Metric | WNEB | LCTX |
|---|---|---|
| Price | $13.97 | $1.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $13.67 | $6.25 |
| AVG Volume (30 Days) | 43.4K | ★ 1.1M |
| Earning Date | 04-28-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.00% | N/A |
| EPS Growth | ★ 33.93 | N/A |
| EPS | ★ 0.42 | N/A |
| Revenue | $44,000.00 | ★ $14,556,000.00 |
| Revenue This Year | N/A | $109.40 |
| Revenue Next Year | $7.25 | N/A |
| P/E Ratio | $33.02 | ★ N/A |
| Revenue Growth | N/A | ★ 53.24 |
| 52 Week Low | $10.78 | $0.91 |
| 52 Week High | $15.01 | $2.09 |
| Indicator | WNEB | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 55.14 | 47.73 |
| Support Level | $13.34 | $1.02 |
| Resistance Level | $14.14 | $1.18 |
| Average True Range (ATR) | 0.36 | 0.06 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 75.27 | 49.98 |
Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the company's revenues, profits, and assets are derived by the Bank from banking products and services.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.